CN104555980B - A kind of carbon quantum dot based on aspirin and biologic applications thereof - Google Patents
A kind of carbon quantum dot based on aspirin and biologic applications thereof Download PDFInfo
- Publication number
- CN104555980B CN104555980B CN201410798808.9A CN201410798808A CN104555980B CN 104555980 B CN104555980 B CN 104555980B CN 201410798808 A CN201410798808 A CN 201410798808A CN 104555980 B CN104555980 B CN 104555980B
- Authority
- CN
- China
- Prior art keywords
- carbon quantum
- aspirin
- quantum dots
- prepared
- based carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 title claims abstract description 100
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 80
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims abstract description 9
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000003384 imaging method Methods 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000746 purification Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 238000002390 rotary evaporation Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 8
- 230000003908 liver function Effects 0.000 abstract description 7
- 230000003907 kidney function Effects 0.000 abstract description 6
- 210000002216 heart Anatomy 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 239000002086 nanomaterial Substances 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 229940113118 carrageenan Drugs 0.000 abstract description 3
- 235000010418 carrageenan Nutrition 0.000 abstract description 3
- 229920001525 carrageenan Polymers 0.000 abstract description 3
- 239000000679 carrageenan Substances 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract description 3
- 208000038016 acute inflammation Diseases 0.000 abstract description 2
- 230000006022 acute inflammation Effects 0.000 abstract description 2
- 230000009977 dual effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 231100001231 less toxic Toxicity 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000024 high-resolution transmission electron micrograph Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
基于阿司匹林的碳量子点及细胞成像及抗炎治疗方面的应用,属于纳米药物技术领域。具体涉及在水合肼溶液促进阿司匹林溶解的情形下,利用微波加热法将其制备成具有强荧光性质的碳量子点。该方法制备的碳量子点在高盐浓度和生理pH条件下非常稳定,保持了蓝色荧光,并可进入细胞核,对细胞进行有效示踪;同时还保留了阿司匹林原有的抗炎功效,在利用角叉菜胶构建的急性炎症模型中,可有效抑制炎细胞产生;此外,所制备的阿司匹林碳量子点毒性较小,在体内应用不会对肝功、肾功以及心、肝、脾、肾等脏器产生影响,可实现纳米材料具有诊治双重功效的目标。
The application of aspirin-based carbon quantum dots and cell imaging and anti-inflammatory treatment belongs to the field of nano-medicine technology. It specifically relates to the preparation of carbon quantum dots with strong fluorescent properties by using microwave heating method under the condition that hydrazine hydrate solution promotes the dissolution of aspirin. The carbon quantum dots prepared by this method are very stable under high salt concentration and physiological pH conditions, maintain blue fluorescence, and can enter the nucleus to effectively trace the cells; meanwhile, the original anti-inflammatory effect of aspirin is retained In the acute inflammation model constructed with carrageenan, the production of inflammatory cells can be effectively inhibited; in addition, the prepared aspirin carbon quantum dots are less toxic, and the application in vivo will not affect liver function, kidney function and heart, liver, spleen, Kidney and other organs are affected, and the goal of nanomaterials with dual functions of diagnosis and treatment can be realized.
Description
技术领域technical field
本发明属于纳米药物技术领域,具体涉及制备一种基于阿司匹林的碳量子点,该碳量子点通过微波加热阿司匹林和水合肼即可获得,具有强荧光性质,且保留了阿司匹林的药物活性,因而可以应用于细胞成像及抗炎治疗方面。The invention belongs to the technical field of nanomedicine, and specifically relates to the preparation of an aspirin-based carbon quantum dot, which can be obtained by heating aspirin and hydrazine hydrate with microwaves, has strong fluorescent properties, and retains the drug activity of aspirin, so it can be Applied to cell imaging and anti-inflammatory therapy.
背景技术Background technique
近些年来,纳米技术用于基因/药物的转运和治疗,或用作诊断探针在医学中得以应用,这种纳米技术与医学的结合称为纳米医学。而这一领域面临的核心问题是如何设计一种多功能的纳米材料,既能够用于疾病的诊断,又可用作疾病的治疗。具有荧光性质的碳量子点作为碳纳米材料家族的新成员,在纳米技术领域引起了学者的广泛关注。这些表面钝化的碳量子点尺寸通常小于10nm,由于具有稳定的荧光性质,宽激发谱和可调的发射峰位等优势被应用于生物标记。与传统的有机染料和半导体量子点相比,碳量子点具有良好的生物相容性和低毒性,因此,在纳米医学中具有良好的应用前景。In recent years, nanotechnology has been used in the transfer and treatment of genes/drugs, or as a diagnostic probe in medicine. The combination of nanotechnology and medicine is called nanomedicine. The core problem facing this field is how to design a multifunctional nanomaterial that can be used not only for disease diagnosis but also for disease treatment. As a new member of the family of carbon nanomaterials, carbon quantum dots with fluorescent properties have attracted widespread attention from scholars in the field of nanotechnology. These surface-passivated carbon quantum dots are usually less than 10nm in size and have been applied to biomarkers due to their stable fluorescence properties, wide excitation spectrum and tunable emission peak. Compared with traditional organic dyes and semiconductor quantum dots, carbon quantum dots have good biocompatibility and low toxicity, so they have good application prospects in nanomedicine.
作为非甾体抗炎药主要代表,阿司匹林(乙酰水杨酸)已经有上百年的历史,其作用虽已得到认可,但尚存在损伤胃肠道、水溶性差等问题。尽管对于阿司匹林的改性从未停止,但真正能被实际应用的却很少。因此,找到一种既能提高阿司匹林的水溶性,又能减轻其对胃肠道的损伤是解决这一问题的关键。As the main representative of non-steroidal anti-inflammatory drugs, aspirin (acetylsalicylic acid) has a history of hundreds of years. Although its effect has been recognized, there are still problems such as damage to the gastrointestinal tract and poor water solubility. Although the modification of aspirin has never stopped, there are very few that can be actually applied. Therefore, finding one that can improve the water solubility of aspirin and reduce its damage to the gastrointestinal tract is the key to solving this problem.
目前,碳量子点在生物医学中主要用于生物成像或药物/基因的转运,而将药物直接做成碳量子点的研究却未见报道,对于药物做成碳量子点后生物学活性是否保留更未见研究。如能将阿司匹林制备成碳量子点,既能改善其水溶性,又能在示踪、抗炎及防治心脑血管疾病方面具有应用前景。At present, carbon quantum dots are mainly used in biomedicine for bioimaging or drug/gene transfer, but the research on making drugs directly into carbon quantum dots has not been reported. Whether the biological activity of drugs is preserved after making carbon quantum dots No research has been seen. If aspirin can be prepared into carbon quantum dots, it can not only improve its water solubility, but also have application prospects in tracing, anti-inflammation, and prevention and treatment of cardiovascular and cerebrovascular diseases.
发明内容Contents of the invention
本发明的目的在于提供一种基于阿司匹林的多功能碳量子点及生物应用。通过对传统药物阿司匹林的改性,水溶性得到提高。本发明制备的碳量子点在高盐浓度和生理pH条件下非常稳定,保持了蓝色荧光,并可进入细胞核,对细胞进行有效示踪;同时还保留了阿司匹林原有的抗炎功效,在利用角叉菜胶构建的急性炎症模型中,可有效抑制炎细胞产生;此外,所制备的阿司匹林碳量子点毒性较小,在体内应用不会对肝功、肾功以及心、肝、脾、肾等脏器产生影响,可实现纳米材料具有诊治双重功效的目标。The object of the present invention is to provide a multifunctional carbon quantum dot based on aspirin and its biological application. By modifying the traditional drug aspirin, the water solubility is improved. The carbon quantum dots prepared by the present invention are very stable under high salt concentration and physiological pH conditions, maintain blue fluorescence, and can enter the nucleus to effectively trace the cells; meanwhile, they also retain the original anti-inflammatory effect of aspirin. In the acute inflammation model constructed with carrageenan, the production of inflammatory cells can be effectively inhibited; in addition, the prepared aspirin carbon quantum dots are less toxic, and the application in vivo will not affect liver function, kidney function and heart, liver, spleen, Kidneys and other organs can be affected, and the goal of nanomaterials with dual functions of diagnosis and treatment can be realized.
本发明利用微波加热方法,前期将阿司匹林在水合肼的辅助作用下溶于去离子水中,微波加热后即可得到强荧光、具有药物活性的碳量子点,其尺寸分布在2~6nm。经过分离提纯后,这种碳量子点可以应用于细胞成像及抗炎治疗方面。The invention utilizes a microwave heating method to dissolve aspirin in deionized water with the assistance of hydrazine hydrate in the early stage, and then obtain strong fluorescent and pharmaceutically active carbon quantum dots with a size distribution of 2 to 6 nm after microwave heating. After separation and purification, this carbon quantum dot can be used in cell imaging and anti-inflammatory treatment.
本发明采用的原料都是商业上可以直接买到的物质,不需要进一步处理,按照一定比例直接混合即可,因此实验操作简便,危险性小,并且具有良好的实验重复性,可以批量生产,同时得到的碳量子点具有高荧光量子效率。The raw materials used in the present invention are all commercially available substances, without further treatment, and can be directly mixed according to a certain ratio, so the experimental operation is simple, the risk is small, and it has good experimental repeatability, and can be produced in batches. At the same time, the obtained carbon quantum dots have high fluorescence quantum efficiency.
本发明所述的基于阿司匹林的碳量子点的制备,包括如下步骤:(1)通过微波法制备基于阿司匹林的碳量子点;(2)对所制备的碳量子点进行分离提纯。The preparation of the aspirin-based carbon quantum dots of the present invention comprises the following steps: (1) preparing the aspirin-based carbon quantum dots by a microwave method; (2) separating and purifying the prepared carbon quantum dots.
(1)基于阿司匹林的碳量子点的制备:将1.0~2.5g阿司匹林加入到含有0.5~2mL、质量浓度98%水合肼的水溶液中,整个体系的总体积控制在10~20mL;而后将该溶液放入微波炉中,在80~100W下加热6~10分钟,从而得到具有蓝色荧光的碳量子点;(1) Preparation of aspirin-based carbon quantum dots: Add 1.0 to 2.5 g of aspirin to an aqueous solution containing 0.5 to 2 mL of hydrazine hydrate with a mass concentration of 98%, and the total volume of the entire system is controlled at 10 to 20 mL; then the solution is Put it into a microwave oven and heat it at 80-100W for 6-10 minutes to obtain carbon quantum dots with blue fluorescence;
(2)碳量子点的分离提纯:向步骤(1)所制备的碳量子点中加入50~100mL去离子水中,超声分散产物,然后用分子量为1800~10000的渗析袋分离提纯所制备的碳量子点,渗析3~7天后,将渗析袋内产物用孔径为0.22~0.45μm的水系滤头过滤,所得产物经过旋转蒸发后浓缩至10~20mL,最后冻干浓缩液,得到棕黄色的基于阿司匹林的碳量子点粉末。(2) Separation and purification of carbon quantum dots: add 50 to 100 mL of deionized water to the carbon quantum dots prepared in step (1), ultrasonically disperse the product, and then separate and purify the prepared carbon with a molecular weight of 1800 to 10,000. Quantum dots, after 3-7 days of dialysis, filter the product in the dialysis bag with a water-based filter head with a pore size of 0.22-0.45 μm, and concentrate the product to 10-20 mL after rotary evaporation, and finally freeze-dry the concentrate to obtain a brown-yellow Carbon quantum dot powder for aspirin.
附图说明Description of drawings
图1:利用微波法制备的基于阿司匹林的碳量子点的透射电镜照片(a),粒径尺寸分布图(b),高分辨透射电镜照片(c),以及粉末衍射谱图(d),说明所制备的碳量子点尺寸分布较窄、单分散性好,具有明显的晶格;Figure 1: Transmission electron micrograph (a), particle size distribution (b), high-resolution transmission electron micrograph (c), and powder diffraction spectrum (d) of aspirin-based carbon quantum dots prepared by microwave method, illustrating The prepared carbon quantum dots have narrow size distribution, good monodispersity, and obvious crystal lattice;
图2:利用微波法制备的基于阿司匹林的碳量子点的紫外吸收谱图(a),荧光激发谱(b中实线)和发射谱(b中虚线),以及碳量子点在室光下(b中左插图)和紫外光下(b中右插图)的照片,说明所制备的碳量子点具有很强的蓝色荧光;Figure 2: The ultraviolet absorption spectrum (a) of aspirin-based carbon quantum dots prepared by microwave method, the fluorescence excitation spectrum (solid line in b) and emission spectrum (dotted line in b), and the carbon quantum dots under room light ( Photos of left inset in b) and photos under ultraviolet light (right inset in b), indicating that the prepared carbon quantum dots have strong blue fluorescence;
图3:利用微波法制备的基于阿司匹林的碳量子点的红外谱图,说明所制备的碳量子点保留了阿司匹林中的乙酰基基团;Figure 3: The infrared spectrum of aspirin-based carbon quantum dots prepared by the microwave method, indicating that the prepared carbon quantum dots retain the acetyl group in aspirin;
图4:利用微波法制备的基于阿司匹林的碳量子点在不同浓度KCl盐溶液中的稳定性曲线(a),以及在不同pH溶液中的稳定性曲线(b),说明碳量子点具有很好的稳定性,可以应用于生物体系;Figure 4: Stability curves (a) of aspirin-based carbon quantum dots in different concentrations of KCl salt solutions prepared by microwave method, and stability curves (b) in different pH solutions, indicating that carbon quantum dots have good Stability, can be applied to biological systems;
图5:利用所制备的基于阿司匹林的碳量子点与子宫颈癌细胞共培养后的共聚焦显微镜图片。波长为400nm的光激发下的暗场图片(a),明场图片(b),以及明场暗场叠加后图片(c),说明碳量子点可以用于细胞成像;Figure 5: Confocal microscope images of the aspirin-based carbon quantum dots co-cultured with cervical cancer cells. The dark field picture (a), the bright field picture (b) and the superimposed picture (c) of the bright field and dark field under the excitation of light with a wavelength of 400nm indicate that carbon quantum dots can be used for cell imaging;
图6:利用所制备的碳量子点在大鼠体内抗炎效果组织学切片结果。空白对照组(a,b,c)炎细胞层较厚,有大量炎细胞,而阿司匹林组(d,e,f)和基于阿司匹林的碳量子点组(g,h,i)炎症明显减轻,炎细胞相对减少;Figure 6: Histological section results of the anti-inflammatory effect of the prepared carbon quantum dots in rats. The blank control group (a, b, c) had a thicker inflammatory cell layer with a large number of inflammatory cells, while the aspirin group (d, e, f) and aspirin-based carbon quantum dots group (g, h, i) had significantly reduced inflammation, The relative reduction of inflammatory cells;
图7:阿司匹林与基于阿司匹林的碳量子点对血清生化指标的影响。基于阿司匹林的碳量子点对肝脏功能指标谷丙转氨酶(a),和谷草转氨酶(b)无明显影响,对肾功能指标尿素氮(c)和肌酐(d)也无明显影响;Figure 7: Effects of aspirin and aspirin-based carbon quantum dots on serum biochemical indicators. Aspirin-based carbon quantum dots had no significant effect on liver function indexes alanine aminotransferase (a) and aspartate aminotransferase (b), and had no significant effect on kidney function indexes urea nitrogen (c) and creatinine (d);
图8:阿司匹林与基于阿司匹林的碳量子点对脏器的影响。腹腔注射碳量子点组大鼠的心(i),肝(j),脾(k),肾(l)与空白对照组(a,b,c,d)和阿司匹林组(e,f,g,h)中的相应器官无明显组织学差异。Figure 8: Effects of aspirin and aspirin-based carbon quantum dots on organs. Heart (i), liver (j), spleen (k), kidney (l) of rats in intraperitoneal injection of carbon quantum dots group and blank control group (a, b, c, d) and aspirin group (e, f, g , h) There were no obvious histological differences in the corresponding organs.
具体实施方式detailed description
下面结合实施例对本发明做进一步的阐述,而不是要以此对本发明进行限制。The present invention will be further described below in conjunction with the examples, rather than limiting the present invention.
实施例1Example 1
(1)基于阿司匹林的碳量子点的制备:将2g乙酰水杨酸加入到含有1.08mL质量浓度为98%的水合肼水溶液中,整个体系的总体积为10mL。微波功率为100W,时间为8分钟。得到具有蓝色荧光的基于阿司匹林的碳量子点。(1) Preparation of aspirin-based carbon quantum dots: 2 g of acetylsalicylic acid was added to 1.08 mL of an aqueous solution of hydrazine hydrate with a mass concentration of 98%, and the total volume of the entire system was 10 mL. The microwave power is 100W, and the time is 8 minutes. Aspirin-based carbon quantum dots with blue fluorescence were obtained.
(2)碳量子点的分离提纯:向步骤(1)所制备的碳量子点中加入80mL去离子水,超声分散产物,用分子量为3500的渗析袋分离提纯所制备的碳量子点,渗析7天后,用粒径为0.22μm的水系滤头过滤所得产物,经过旋转蒸发后浓缩至10mL后,冻干得到基于阿司匹林的碳量子点粉末(棕黄色),产量约为50mg。(2) Separation and purification of carbon quantum dots: add 80 mL of deionized water to the carbon quantum dots prepared in step (1), ultrasonically disperse the product, separate and purify the prepared carbon quantum dots with a molecular weight of 3500, and dialysis for 7 Days later, the obtained product was filtered with a water-based filter head with a particle size of 0.22 μm, concentrated to 10 mL after rotary evaporation, and then freeze-dried to obtain aspirin-based carbon quantum dot powder (brown yellow), with a yield of about 50 mg.
透射电镜下观察可见所得到的基于阿司匹林的碳量子点尺寸分布在2~6nm,如图1所示。Observation under a transmission electron microscope shows that the obtained aspirin-based carbon quantum dots have a size distribution of 2-6 nm, as shown in FIG. 1 .
实施例2Example 2
(1)基于阿司匹林的碳量子点的制备:将1g乙酰水杨酸加入到含有1.08mL的98%水合肼的水溶液中,整个体系的总体积为10mL。微波功率为100W,时间为7分钟。得到具有蓝色荧光的基于阿司匹林的碳量子点。(1) Preparation of aspirin-based carbon quantum dots: 1 g of acetylsalicylic acid was added to an aqueous solution containing 1.08 mL of 98% hydrazine hydrate, and the total volume of the entire system was 10 mL. The microwave power is 100W, and the time is 7 minutes. Aspirin-based carbon quantum dots with blue fluorescence were obtained.
(2)碳量子点的分离提纯:向步骤(1)所制备的碳量子点中加入50mL去离子水,超声分散产物,用分子量为3500的渗析袋分离提纯所制备的碳量子点,渗析7天后,用粒径为0.22μm的水系滤头过滤所得产物,经过旋转蒸发后浓缩至5mL,冻干得到基于阿司匹林的碳量子点粉末(棕黄色),产量约为30mg。所得碳量子点具有强荧光性质,如图2b所示。(2) Separation and purification of carbon quantum dots: add 50 mL of deionized water to the carbon quantum dots prepared in step (1), ultrasonically disperse the product, separate and purify the prepared carbon quantum dots with a molecular weight of 3500, and dialysis for 7 Days later, the obtained product was filtered with a water-based filter head with a particle size of 0.22 μm, concentrated to 5 mL after rotary evaporation, and freeze-dried to obtain aspirin-based carbon quantum dot powder (brown yellow), with a yield of about 30 mg. The resulting carbon quantum dots have strong fluorescent properties, as shown in Figure 2b.
实施例3Example 3
(1)基于阿司匹林的碳量子点的制备:将2g乙酰水杨酸加入到含有0.54mL的98%水合肼的水溶液中,整个体系的总体积为10mL。微波功率为100W,时间为8分钟。得到具有蓝色荧光的基于阿司匹林的碳量子点。(1) Preparation of aspirin-based carbon quantum dots: 2 g of acetylsalicylic acid was added to an aqueous solution containing 0.54 mL of 98% hydrazine hydrate, and the total volume of the entire system was 10 mL. The microwave power is 100W, and the time is 8 minutes. Aspirin-based carbon quantum dots with blue fluorescence were obtained.
(2)碳量子点的分离提纯:向步骤(1)所制备的碳量子点中加入60mL去离子水,超声分散产物,用分子量为3500的渗析袋分离提纯所制备的碳量子点,渗析7天后,用粒径为0.45μm的水系滤头过滤所得产物,经过旋转蒸发后浓缩至5mL后,冻干得到基于阿司匹林的碳量子点粉末(棕黄色),产量约为40mg。经过红外测试,可知碳量子点保留了阿司匹林中的乙酰基,如图3所示(2) Separation and purification of carbon quantum dots: add 60 mL of deionized water to the carbon quantum dots prepared in step (1), ultrasonically disperse the product, separate and purify the prepared carbon quantum dots with a molecular weight of 3500, and dialysis for 7 Days later, the obtained product was filtered with a water-based filter head with a particle size of 0.45 μm, concentrated to 5 mL after rotary evaporation, and then freeze-dried to obtain aspirin-based carbon quantum dot powder (brown yellow), with a yield of about 40 mg. After infrared testing, it can be seen that carbon quantum dots retain the acetyl group in aspirin, as shown in Figure 3
实施例4Example 4
(1)基于阿司匹林的碳量子点的制备:将2g乙酰水杨酸加入到含有2.16mL的98%水合肼的水溶液中,整个体系的总体积为10mL。微波功率为100W,时间为8分钟。得到具有蓝色荧光的基于阿司匹林的碳量子点。(1) Preparation of aspirin-based carbon quantum dots: 2 g of acetylsalicylic acid was added to an aqueous solution containing 2.16 mL of 98% hydrazine hydrate, and the total volume of the entire system was 10 mL. The microwave power is 100W, and the time is 8 minutes. Aspirin-based carbon quantum dots with blue fluorescence were obtained.
(2)碳量子点的分离提纯:向步骤(1)所制备的碳量子点中加入80mL去离子水,超声分散产物,用分子量为3500的渗析袋分离提纯所制备的碳量子点,渗析7天后,用粒径为0.22μm的水系滤头过滤所得产物,经过旋转蒸发后浓缩至10mL后,冻干得到基于阿司匹林的碳量子点粉末(棕黄色),产量约为50mg。而后配制浓度为0、0.25、0.5、0.75、1.0、1.25、1.5、1.75和2.0mol/L的KCl盐溶液,以及利用盐酸和氢氧化钠调节去离子水得到的pH为1.8、2.3、3.2、4.2、4.9、6.1、7.2、8.1、8.9、9.8、10.8和12.5的水溶液,随后在上述每种溶液(3mL)中加入0.1g的碳量子点,最后检测溶液荧光强度,如图4所示。(2) Separation and purification of carbon quantum dots: add 80 mL of deionized water to the carbon quantum dots prepared in step (1), ultrasonically disperse the product, separate and purify the prepared carbon quantum dots with a molecular weight of 3500, and dialysis for 7 Days later, the obtained product was filtered with a water-based filter head with a particle size of 0.22 μm, concentrated to 10 mL after rotary evaporation, and then freeze-dried to obtain aspirin-based carbon quantum dot powder (brown yellow), with a yield of about 50 mg. Then preparation concentration is the KCl salt solution of 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75 and 2.0mol/L, and utilizes hydrochloric acid and sodium hydroxide to adjust the pH obtained by deionized water to be 1.8, 2.3, 3.2, 4.2, 4.9, 6.1, 7.2, 8.1, 8.9, 9.8, 10.8 and 12.5 aqueous solutions, then add 0.1g of carbon quantum dots to each of the above solutions (3mL), and finally detect the fluorescence intensity of the solution, as shown in Figure 4.
实施例5Example 5
(1)基于阿司匹林的碳量子点的制备和提纯如实施例1所述。(1) The preparation and purification of aspirin-based carbon quantum dots are as described in Example 1.
(2)由于所制备的基于阿司匹林的碳量子点具有荧光性质,考虑其可用于细胞标记。将人子宫颈癌细胞以20万/孔接种于共聚焦显微镜专用平皿中,在含5%二氧化碳的37℃细胞培养箱中培养。过夜细胞贴壁后,更换培养基,加入碳量子点,终浓度为20μg/mL。共培养6小时后,弃培养基,磷酸缓冲盐溶液冲洗2遍,4%多聚甲醛固定10分钟,磷酸缓冲盐溶液冲洗2遍。当激发波长为400nm时,激光共聚焦显微镜下观察可见,整个细胞呈蓝色(图5),说明碳量子点进入细胞浆,并可穿过核膜,进入细胞核,对细胞进行有效标记。(2) Since the prepared aspirin-based carbon quantum dots have fluorescent properties, it is considered that they can be used for cell labeling. Human cervical cancer cells were inoculated at 200,000/well in a confocal microscope special plate, and cultured in a 37°C cell culture incubator containing 5% carbon dioxide. After overnight cell attachment, the medium was replaced and carbon quantum dots were added to a final concentration of 20 μg/mL. After co-cultivation for 6 hours, the medium was discarded, washed twice with phosphate buffered saline, fixed with 4% paraformaldehyde for 10 minutes, and washed twice with phosphate buffered saline. When the excitation wavelength is 400nm, it can be seen under the laser confocal microscope that the whole cell is blue (Figure 5), indicating that the carbon quantum dots enter the cytoplasm, and can pass through the nuclear membrane and enter the nucleus to effectively label the cells.
实施例6Example 6
(1)基于阿司匹林的碳量子点的制备和提纯如实施例1所述。(1) The preparation and purification of aspirin-based carbon quantum dots are as described in Example 1.
(2)由于阿司匹林发挥抗炎作用的机制是其酯键通过与环氧合酶的丝氨酸残基发生乙酰化反应,从而抑制前列腺素E2形成,发挥抗炎作用,而我们在反应中并没有破坏阿司匹林的酯键,因此理论上说明其生物学作用应该保留。为考察所制备的基于阿司匹林的碳量子点的生物学活性,我们选取雄性Wistar大鼠(160~180g),分别腹腔注射等体积的磷酸缓冲盐溶液,阿司匹林和基于阿司匹林的碳量子点(20mg/kg)溶液。半小时后,将尺寸为2.0×1.0×0.5cm的聚酯纤维海绵浸润在质量浓度为1%的角叉菜胶溶液后,取出,植入大鼠背部皮下,最后用3/0手术缝合线缝合。术后5小时,质量浓度为4%的多聚甲醛心脏灌流固定处死,取皮下组织,固定,逐级脱水,进行组织学染色。(2) The mechanism of aspirin's anti-inflammatory effect is that its ester bond undergoes an acetylation reaction with the serine residue of cyclooxygenase, thereby inhibiting the formation of prostaglandin E2 and exerting an anti-inflammatory effect, but we did not destroy it in the reaction Aspirin's ester bond, so theoretically its biological effects should be preserved. In order to investigate the biological activity of the prepared aspirin-based carbon quantum dots, we selected male Wistar rats (160-180g) and injected equal volumes of phosphate-buffered saline, aspirin and aspirin-based carbon quantum dots (20mg/ kg) solution. After half an hour, a polyester fiber sponge with a size of 2.0×1.0×0.5 cm was soaked in a carrageenan solution with a mass concentration of 1%, taken out, implanted subcutaneously in the back of the rat, and finally closed with a 3/0 surgical suture suture. Five hours after the operation, the heart was perfused with 4% paraformaldehyde and sacrificed, and the subcutaneous tissue was taken, fixed, and dehydrated step by step for histological staining.
显微镜下观察可见,空白对照组(注射磷酸缓冲盐溶液)炎细胞层较厚,有大量炎细胞,如中性粒细胞、淋巴细胞浸润(图6);而注射阿司匹林和基于阿司匹林的碳量子点组(图6),炎症明显减轻,炎细胞相对减少。说明基于阿司匹林的碳量子点仍保留了原有的抗炎活性,且效果要优于单纯药物阿司匹林。分析原因,一方面由于纳米材料比表面积相对较大,因为单位体积中其表面结合位点相对较多;另一方面,碳量子点比单纯药物阿司匹林水溶性有所提高,且略带正电,可促进其在体内循环和进入细胞中。Observation under a microscope showed that the blank control group (injected with phosphate buffered saline) had a thicker inflammatory cell layer, with a large number of inflammatory cells, such as neutrophils and lymphocytes infiltrating (Figure 6); while the injection of aspirin and aspirin-based carbon quantum dots group (Figure 6), the inflammation was significantly reduced, and the inflammatory cells were relatively reduced. It shows that the aspirin-based carbon quantum dots still retain the original anti-inflammatory activity, and the effect is better than that of aspirin alone. Analysis of the reasons, on the one hand, due to the relatively large specific surface area of nanomaterials, because there are relatively more surface binding sites per unit volume; on the other hand, carbon quantum dots have improved water solubility compared with the simple drug aspirin, and are slightly positively charged. Can promote its circulation in the body and into cells.
实施例7Example 7
(1)基于阿司匹林的碳量子点的制备和提纯如实施例1所述。(1) The preparation and purification of aspirin-based carbon quantum dots are as described in Example 1.
(2)为考察所制备的基于阿司匹林的碳量子点的生物毒性。我们通过体内动物实验,观察了其对血清生化中肝功、肾功等指标的影响。雄性Wistar大鼠(160~180g)分别腹腔注射等体积的磷酸缓冲盐溶液,阿司匹林和基于阿司匹林的碳量子点(20mg/kg)溶液。分别于1,3和7天取眼球血,收集于不含肝素的采血管中,静置1~2小时,3000rpm离心5分钟,取上清用于生化指标检测。(2) To investigate the biological toxicity of the prepared aspirin-based carbon quantum dots. Through animal experiments in vivo, we have observed its effects on serum biochemical indicators such as liver function and kidney function. Male Wistar rats (160-180 g) were intraperitoneally injected with equal volumes of phosphate buffered saline, aspirin and aspirin-based carbon quantum dots (20 mg/kg) solution. Eye blood was collected on days 1, 3 and 7, collected in heparin-free blood collection tubes, left to stand for 1 to 2 hours, centrifuged at 3000 rpm for 5 minutes, and the supernatant was used for detection of biochemical indicators.
谷丙转氨酶和谷草转氨酶是肝脏功能的重要检测指标,与空白对照组(注射磷酸缓冲盐溶液)相比,阿司匹林组和基于阿司匹林的碳量子点组虽略有差异(图7),但该差异没有统计学意义,且各组指标均在正常范围内,说明对肝脏功能无明显影响。尿素氮和肌酐是肾功能的重要评价指标,与空白对照组相比,阿司匹林组和基于阿司匹林的碳量子点组均在正常范围内(图7),无明显差异。以上血清生化检测,初步说明所制备的基于阿司匹林的碳量子点生物安全性较好,对肝脏和肾脏功能无明显影响。Alanine aminotransferase and aspartate aminotransferase are important indicators of liver function. Compared with the blank control group (injection of phosphate-buffered saline), the aspirin group and the aspirin-based carbon quantum dot group were slightly different (Figure 7), but the difference There was no statistical significance, and the indicators in each group were within the normal range, indicating that there was no significant effect on liver function. Blood urea nitrogen and creatinine are important evaluation indicators of renal function. Compared with the blank control group, the aspirin group and the aspirin-based carbon quantum dots group were both within the normal range (Figure 7), with no significant difference. The above serum biochemical tests preliminarily indicate that the prepared aspirin-based carbon quantum dots have good biological safety and have no significant effect on liver and kidney functions.
实施例8Example 8
(1)基于阿司匹林的碳量子点的制备和提纯如实施例1所述。(1) The preparation and purification of aspirin-based carbon quantum dots are as described in Example 1.
(2)关于对基于阿司匹林的碳量子点的生物毒性考察,除取眼球血进行血清生化分析外,同时4%多聚甲醛对大鼠(实施例7中)灌流固定,取心、肝、脾和肾等器官进行固定、逐级脱水和组织学染色,以明确基于阿司匹林的碳量子点是否会引起脏器的损伤、炎症或其它病变。(2) Regarding the biological toxicity investigation of aspirin-based carbon quantum dots, in addition to taking eyeball blood for serum biochemical analysis, at the same time, 4% paraformaldehyde was perfused and fixed to rats (in Example 7), and heart, liver, and spleen were taken. Fixation, step-by-step dehydration, and histological staining of kidneys and other organs to clarify whether aspirin-based carbon quantum dots can cause organ damage, inflammation, or other lesions.
显微镜下观察可见,与空白对照组相比,阿司匹林组和基于阿司匹林的碳量子点组没有明显的组织学变化(图8),说明生物安全性较好,不会引起脏器损伤、炎症或其它病变。Observation under a microscope shows that compared with the blank control group, the aspirin group and the aspirin-based carbon quantum dots group have no obvious histological changes (Figure 8), indicating that the biological safety is better and will not cause organ damage, inflammation or other damage. lesion.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410798808.9A CN104555980B (en) | 2014-12-20 | 2014-12-20 | A kind of carbon quantum dot based on aspirin and biologic applications thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410798808.9A CN104555980B (en) | 2014-12-20 | 2014-12-20 | A kind of carbon quantum dot based on aspirin and biologic applications thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104555980A CN104555980A (en) | 2015-04-29 |
CN104555980B true CN104555980B (en) | 2016-06-22 |
Family
ID=53073192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410798808.9A Expired - Fee Related CN104555980B (en) | 2014-12-20 | 2014-12-20 | A kind of carbon quantum dot based on aspirin and biologic applications thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104555980B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108101019A (en) * | 2017-12-19 | 2018-06-01 | 重庆文理学院 | A kind of method that carbon quantum dot is prepared using expired Chinese patent drug |
CN111077126A (en) * | 2019-12-31 | 2020-04-28 | 江苏大学 | Preparation method and application of molecular imprinting fluorescence sensor based on N-CQDs |
CN114804071A (en) * | 2022-04-21 | 2022-07-29 | 复旦大学附属眼耳鼻喉科医院 | Carbon quantum dot material with oxidation resistance and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103693633A (en) * | 2013-12-04 | 2014-04-02 | 上海交通大学 | Method for green synthesis of fluorescent chiral carbon dots |
CN103771390A (en) * | 2014-01-06 | 2014-05-07 | 上海交通大学 | Method for synthesizing carbon quantum dot by using biologic active enzyme auxiliary microwave method, carbon quantum dot prepared by using method, and application thereof |
CN104192827A (en) * | 2014-08-26 | 2014-12-10 | 上海交通大学 | Method for synthesizing carbon quantum dots on basis of organic micromolecule microwave solid-phase reaction |
-
2014
- 2014-12-20 CN CN201410798808.9A patent/CN104555980B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103693633A (en) * | 2013-12-04 | 2014-04-02 | 上海交通大学 | Method for green synthesis of fluorescent chiral carbon dots |
CN103771390A (en) * | 2014-01-06 | 2014-05-07 | 上海交通大学 | Method for synthesizing carbon quantum dot by using biologic active enzyme auxiliary microwave method, carbon quantum dot prepared by using method, and application thereof |
CN104192827A (en) * | 2014-08-26 | 2014-12-10 | 上海交通大学 | Method for synthesizing carbon quantum dots on basis of organic micromolecule microwave solid-phase reaction |
Non-Patent Citations (1)
Title |
---|
"Microwave assisted one-step green synthesis of cell-permeable multicolor photoluminescent carbon dots without surface passivation reagents";Xiaohui Wang et al.;《Journal of Materials Chemistry》;20110118;第21卷;第2445-2450页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104555980A (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Quantum dots in cell imaging and their safety issues | |
Wang et al. | Fabrication of red blood cell-based multimodal theranostic probes for second near-infrared window fluorescence imaging-guided tumor surgery and photodynamic therapy | |
Shen et al. | CMCTS stabilized Fe 3 O 4 particles with extremely low toxicity as highly efficient near-infrared photothermal agents for in vivo tumor ablation | |
Wang et al. | A theranostic nanoplatform: magneto-gold@ fluorescence polymer nanoparticles for tumor targeting T 1 & T 2-MRI/CT/NIR fluorescence imaging and induction of genuine autophagy mediated chemotherapy | |
Cheng et al. | A colon‐targeted oral probiotics delivery system using an enzyme‐triggered fuse‐like microcapsule | |
Miao et al. | Natural Humic‐Acid‐Based Phototheranostic Agent | |
CN103623437B (en) | A kind of imaging nano-probe material and its preparation method and application | |
CN106729742A (en) | A kind of cancer target sericin micella and its preparation method and application | |
CN104555980B (en) | A kind of carbon quantum dot based on aspirin and biologic applications thereof | |
CN111821283A (en) | A kind of cancer cell membrane-coated zinc glutamate-coated Prussian blue nanoparticles loaded with triphenylphosphine-lonidamine and preparation method thereof | |
Li et al. | The biobehavior, biocompatibility and theranostic application of SPNS and Pd@ Au nanoplates in rats and rabbits | |
CN103784978B (en) | A kind of albumen-dye composition and application thereof | |
Chen et al. | Local delivery of glabridin by biomolecular microneedle to accelerate infected wound healing | |
Lu et al. | MnO 2 doped graphene nanosheets for carotid body tumor combination therapy | |
CN105012962B (en) | The preparation method of triangle build fluorescence fibroin carbon point composite nanometer particle | |
CN104258424A (en) | Compound nano diagnosis and treatment preparation and preparation method thereof | |
CN113144171B (en) | Polypeptide nano-drug with oxidation response morphology transformation | |
CN104721821B (en) | Golden core-shell nano grain preparation method is changed on targeting rare earth | |
CN110368501A (en) | A kind of boron medicine-carried system of RGD peptide modification and its preparation and application | |
CN107884377A (en) | A kind of application based on cell excretion body nanometer aggregate probe and its in cell-targeting fluorescence and magnetic multi-modality imaging preparation is prepared | |
CN103908681B (en) | The application of fluorescent carbon nanoparticle in brain tumor diagnosis that angiopep-2 modifies | |
CN114958363B (en) | Red light-emitting fluorescent carbon dots targeting the Golgi apparatus and their preparation methods and applications | |
CN106512029A (en) | Nano-probe with apoptosis target function and preparation and application | |
CN113633789B (en) | Liquid metal nano probe integrating light acoustic imaging and drug inclusion and preparation method thereof | |
CN117466286A (en) | A red fluorescent carbon quantum dot based on rhein and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Hongchen Inventor after: Xu Xiaowei Inventor after: Zhang Kai Inventor after: Wang Dandan Inventor after: Lin Chongtao Inventor after: Yang Bai Inventor before: Sun Hongchen Inventor before: Xu Xiaowei Inventor before: Zhang Kai Inventor before: Wang Dandan Inventor before: Lin Chongtao Inventor before: Yang Bai |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160622 Termination date: 20211220 |